Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2022-05-23
DOI
10.1080/09546634.2022.2081655
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Five‐year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)
- (2021) D. Thaçi et al. BRITISH JOURNAL OF DERMATOLOGY
- Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison
- (2021) Angelo Ruggiero et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Psoriasis
- (2021) Christopher E M Griffiths et al. LANCET
- Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
- (2021) Matteo Megna et al. Dermatologic Therapy
- Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study
- (2021) Angelo Ruggiero et al. Dermatologic Therapy
- Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients
- (2021) Katharina A. Drerup et al. DERMATOLOGY
- Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment
- (2020) Fathima F. Ismail et al. Dermatologic Therapy
- Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
- (2020) K. B. Gordon et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy of Risankizumab in Patients with Moderate‐to‐Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa‐1 and UltIMMa‐2 Studies
- (2020) Bruce Strober et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study
- (2020) A.‐C. Fougerousse et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open‐label, efficacy assessor‐blinded clinical trial
- (2020) R.B. Warren et al. BRITISH JOURNAL OF DERMATOLOGY
- Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience
- (2020) Matteo Megna et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study
- (2020) F. Benhadou et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
- (2020) Marco Galluzzo et al. Journal of Clinical Medicine
- Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis
- (2020) Matthias Augustin et al. JAMA Dermatology
- Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks
- (2019) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- (2019) Kristian Reich et al. LANCET
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”
- (2018) Matteo Megna et al. CLINICAL RHEUMATOLOGY
- Guselkumab for the treatment of psoriasis
- (2018) Matteo Megna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs
- (2018) M. Megna et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of neutrophils by autocrine IL-17A–IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2
- (2013) Patricia R Taylor et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now